0000000000210995

AUTHOR

Lauro D

showing 2 related works from this author

Polyphenol intake and cardiovascular risk factors in a population with type 2 diabetes: The TOSCA.IT study

2017

Background: The role of polyphenol intake on cardiovascular risk factors is little explored, particularly in people with diabetes. Aim: To evaluate the association between the intake of total polyphenols and polyphenol classes with the major cardiovascular risk factors in a population with type 2 diabetes. Methods: Dietary habits were investigated in 2573 males and females participants of the TOSCA.IT study. The European Prospective Investigation on Cancer and Nutrition (EPIC) questionnaire was used to assess dietary habits. In all participants, among others, we assessed anthropometry, plasma lipids, blood pressure, C-reactive protein and HbA1c following a standard protocol. The USDA and Ph…

Male0301 basic medicinePhysiologyType 2 diabetes030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineSettore MED/13 - Endocrinologiachemistry.chemical_compound0302 clinical medicineDietary polyphenolsFlavonoidsPhenolic acidsCardiovascular riskType 2 diabetesLOW-GRADE INFLAMMATIONBLOOD-PRESSUREDIETARY POLYPHENOLSDARK CHOCOLATEINSULIN SENSITIVITYRANDOMIZED-TRIALSDISEASEMETAANALYSISMETABOLISMCHOLESTEROLRisk FactorsSurveys and QuestionnairesHydroxybenzoatesProspective StudiesFood scienceCardiovascular risk; Dietary polyphenols; Flavonoids; Phenolic acids; Type 2 diabeteseducation.field_of_studyPhenolic acidNutrition and Dieteticsbiologyfood and beveragesType 2 diabetesDietary polyphenolMiddle AgedDietary polyphenols; Flavonoids; Phenolic acids; Cardiovascular risk; Type 2 diabetesEuropean Prospective Investigation into Cancer and NutritionDietary polyphenolsCardiovascular DiseasesFemalePhenolic acidsPopulationCardiovascular risk Dietary polyphenols Flavonoids Phenolic acids Type 2 diabetes03 medical and health sciencesDiabetes mellitusmedicineHumanseducationTriglyceridesAgedFlavonoids030109 nutrition & dieteticsDose-Response Relationship Drugbusiness.industryCholesterol HDLC-reactive proteinPolyphenolsCholesterol LDLAnthropometrymedicine.diseaseCardiovascular riskCardiovascular risk; Dietary polyphenols; Flavonoids; Phenolic acids; Type 2 diabetes; Nutrition and Dietetics; Critical Care and Intensive Care MedicineDietCross-Sectional StudiesNutrition AssessmentDiabetes Mellitus Type 2chemistryFlavonoidbiology.proteinGlycated hemoglobinbusinessBody mass index
researchProduct

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

2015

BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS: In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching individually appropriate glycemic targets in all patients. To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The primary cardiovascular outcome was a composite of cardiovascular deat…

Oralmedicine.medical_specialtyHeart diseasesGlycosylatedAdministration Oralheart failureType 2 diabetesDipeptidyl peptidase-4 inhibitorKaplan-Meier EstimatePlaceboSitagliptin PhosphateSitagliptin Cardiovascular Outcomeschemistry.chemical_compoundDrug TherapyDouble-Blind MethodInternal medicineDiabetes MellitusmedicineHumansHypoglycemic AgentsGlycated HemoglobinHemoglobin A GlycosylatedAdministration Oral; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Drug Therapy Combination; Follow-Up Studies; Heart Diseases; Heart Failure; Hemoglobin A Glycosylated; Hospitalization; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Pyrazines; Sitagliptin Phosphate; Triazoles; Medicine (all)business.industryMedicine (all)SemaglutideSitagliptin PhosphateHemoglobin AGeneral MedicineTriazolesta3121medicine.diseaseSurgeryHospitalizationCardiovascular diseaseschemistryDiabetes Mellitus Type 2SitagliptinPyrazinesAdministrationCombinationDrug Therapy CombinationGlycated hemoglobinbusinessType 2Alogliptinmedicine.drugFollow-Up StudiesNew England Journal of Medicine
researchProduct